PURE Bioscience, Inc., creator of the patented silver dihydrogen citrate (SDC) antimicrobial, has entered into a five-year strategic collaboration agreement with St. Louis-based Intercon Chemical Company (ICC). The agreement consists of a multi-pronged approach to accelerate the commercialization of PURE's unique and proprietary SDC-based products.
The strategic collaboration agreement provides:
ICC licenses from PURE its patents and technology know-how for the exclusive manufacture for PURE of all SDC-based products.
ICC will invest in plant improvements to allow for expanded SDC production.
ICC's R&D team will collaborate on SDC product line development.
ICC licenses the distribution rights for SDC-based products into its core businesses of institutional cleaning and sanitation products.
ICC will develop a new initiative focused on US hospital, healthcare and medical facilities.
PURE earns royalty income on SDC-products sold by ICC and its affiliates.
PURE Forms Strategic Collaboration With Intercon Chemical Company
Published December 13, 2013
Related Breaking News
- Flowcrete Americas and Carboline USA Enter New Distribution Agreement in the USA
- Perstorp Opens New Oxo Plant to Strengthen Position in PVC Plasticizers, Chemical Intermediates
- PPG Launches Metal Coatings Color Selector Tool on ppgideascapes.com
- Daniel Lang Appointed Managing Director of Ennis-Flint EMEA
Related Paint & Coatings Manufacturer News